CG Labz
Peptide Library / Metabolic / Weight Management

Semaglutide

GLP-1 Receptor Agonist

Semaglutide Research Protocol & Titration Reference

Complete Research Guide 6 min read5 peer-reviewed references

Quickstart Overview

Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native GLP-1, modified with a C-18 fatty diacid for albumin binding and an Aib substitution for DPP-IV resistance. It has one of the largest clinical evidence bases of any peptide (SUSTAIN, STEP and SELECT programmes).

Reconstitution
Add 2.0 mL bacteriostatic water to a 5 mg vial → 2.5 mg/mL
Clinical Titration
0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (4-week steps)
Measuring Reference
At 2.5 mg/mL: 0.25 mg = 0.1 mL = 10 units
Frequency
Once weekly, same day each week
Half-life
≈ 7 days (168 h)
Route
Subcutaneous (abdomen, thigh, upper arm)

Scientific Data

Molecular Formula
—
Molecular Weight
4113.58 Da
Sequence
HAEG(Aib)FTSDVSSYLEGQAAKEFIAWLVRGRG
Sequence Length
33
CAS
Research compound
Peptide Family
Incretin mimetic
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 5 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
2.50 mg/mL
Draw Volume
0.100 mL
Syringe Units
10.0 U
Doses / Vial
20

Units assume a U-100 insulin syringe (100 units = 1 mL). Semaglutide is relatively stable in solution — 56 days refrigerated is the labelled stability for pen products.

Frequency: Once weekly

Reconstitution Steps

  1. 1Bring vial to room temperature; swab stoppers.
  2. 2Add 2.0 mL bacteriostatic water slowly down the glass wall.
  3. 3Swirl gently until clear.
  4. 4Label with date and concentration; refrigerate at 2–8 °C.

Supplies Needed

Planning example for the first 16 weeks of standard titration (0.25 → 0.5 → 1.0 → 1.7 mg).

Peptide (5 mg vials)
16 weeks ≈ 13.8 mg total ≈ 3 vials
Bacteriostatic Water
One 10 mL vial
Insulin Syringes (U-100)
16 (one per week)
Alcohol Swabs
2 per administration

Protocol Overview

Goal
Model GLP-1 receptor-mediated effects on glycemic control, appetite and body weight.
Schedule
Weekly, titrated upward every 4 weeks to limit GI effects.
Dose Range
0.25 mg (initiation) to 2.4 mg (maximum studied for weight).
Reconstitution
2.5 mg/mL allows 0.25 mg increments of 10 units.

Dosing Protocol

Weeks 1–4
0.25 mg weekly (initiation, not therapeutic)
Weeks 5–8
0.5 mg weekly
Weeks 9–12
1.0 mg weekly
Weeks 13–16
1.7 mg weekly
Week 17+
2.4 mg weekly (STEP trial maintenance)
Timing
Same day weekly; with or without food; a missed dose may be taken within 5 days

Storage Instructions

Lyophilized
−20 °C long term; 2–8 °C for months
Reconstituted
2–8 °C, up to 56 days
Room temperature
Pen products tolerate ≤ 30 °C for up to 28 days; keep research vials refrigerated
Light
Protect from light

Important Notes

  • Gastrointestinal effects (nausea, constipation) are dose-dependent and the primary reason for the slow titration schedule.
  • Boxed warning in clinical products: thyroid C-cell tumours in rodents — contraindicated in MTC/MEN2 contexts.
  • Pancreatitis, gallbladder events and delayed gastric emptying are recognised in clinical literature.
  • Lean-mass loss accompanies total weight loss; protein intake and resistance training are standard counter-measures in study designs.

How This Works

Semaglutide activates GLP-1 receptors in the pancreas (glucose-dependent insulin secretion, glucagon suppression), the gastrointestinal tract (delayed gastric emptying) and the hypothalamus and hindbrain (reduced appetite and food reward). The C-18 fatty diacid side chain binds albumin, shielding the molecule from renal clearance and extending its half-life to roughly one week. In the SELECT trial it reduced major adverse cardiovascular events by 20% in non-diabetic patients with obesity, suggesting direct cardiometabolic actions beyond weight loss.

Potential Benefits & Side Effects

Reported in research
  • ≈ 15% mean body-weight reduction at 2.4 mg over 68 weeks (STEP 1)
  • HbA1c reduction of 1.5–1.8% in type 2 diabetes (SUSTAIN)
  • 20% reduction in major cardiovascular events (SELECT)
  • Reduced appetite, food cravings and 'food noise'
  • Improvements in blood pressure, lipids and inflammatory markers
  • Emerging data in NASH/MASH, kidney disease and alcohol-use research
Possible considerations
  • Nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%) in STEP 1
  • Delayed gastric emptying; aspiration risk under anaesthesia
  • Gallbladder disease and pancreatitis (rare)
  • Hypoglycaemia when combined with insulin or sulfonylureas
  • Injection-site reactions; fatigue; hair thinning secondary to rapid weight loss

Lifestyle Factors

  • Protein ≥ 1.2–1.6 g/kg/day and resistance training to preserve lean mass
  • Smaller, slower meals and avoiding high-fat foods reduce GI effects
  • Hydration — reduced thirst signalling and GI losses raise dehydration risk
  • Limit alcohol; GLP-1 agonists amplify its effects on gastric emptying

Injection Technique

  1. 1Subcutaneous abdomen (≥ 2 inches from navel), anterior thigh or back of upper arm.
  2. 2Rotate sites weekly; the same region at a different spot is acceptable.
  3. 3Insert at 90° for standard body fat, 45° for lean subjects.
  4. 4Inject slowly over 5 seconds; hold 5–10 seconds before withdrawal.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] New England Journal of Medicine
    Wilding J.P.H. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
    View Source
  2. [2] New England Journal of Medicine
    Lincoff A.M. et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
    View Source
  3. [3] Lancet Diabetes & Endocrinology
    Sorli C. et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1).
    View Source
  4. [4] Journal of Medicinal Chemistry
    Lau J. et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
    View Source
  5. [5] Nature Medicine
    Rubino D.M. et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8).
    View Source